SuperworthAN2 Therapeutics shares outstanding ANTX
Diluted shares outstanding, averaged over each quarter, from 2021.
- Latest quarter, to Jun 30, 2026
- 44.8M
- On a year earlier
- +48.4%
- more shares
AN2 Therapeutics had 44.8M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 48.4% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 30.4M | +2% |
| FY2024 | 29.9M | +0% |
| FY2023 | 29.7M | +54% |
| FY2022 | 19.4M | +629% |
| FY2021 | 2.7M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 44.8M | +48% | |
| Q1 FY26 | 34.1M | +13% | |
| Q4 FY25 | 30.4M | +2% | |
| Q3 FY25 | 30.3M | +1% | |
| Q2 FY25 | 30.2M | +1% | |
| Q1 FY25 | 30.1M | +1% | |
| Q4 FY24 | 29.9M | +0% | |
| Q3 FY24 | 29.8M | +16% | |
| Q2 FY24 | 29.8M | +53% | |
| Q1 FY24 | 29.8M | +54% | |
| Q4 FY23 | 29.7M | +54% | |
| Q3 FY23 | 25.6M | +33% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on AN2 Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.